Tmsb10 Antibody

What is TMSB10 and why is it significant in cancer research?

Thymosin beta 10 (TMSB10) is a member of the thymosin family that plays crucial roles in cytoskeletal organization. It binds to and sequesters actin monomers (G actin), thereby inhibiting actin polymerization . TMSB10 is particularly significant in cancer research because:

• It is frequently upregulated in multiple cancer types including clear cell renal cell carcinoma (ccRCC), bladder cancer, colorectal cancer, and glioma

• Expression levels correlate with clinical parameters such as tumor stage, grade, and patient survival

• It serves as both a diagnostic and prognostic biomarker in cancers like ccRCC with high specificity (area under ROC curve = 0.9543)

• It is involved in tumor microenvironment regulation and immune cell infiltration

The expression of TMSB10 dramatically decreases after birth in normal tissues, making its upregulation in cancer tissues a notable phenomenon for study .

What applications are TMSB10 antibodies commonly used for in research?

TMSB10 antibodies are employed across various experimental techniques:

When choosing applications, researchers should note that validation status varies significantly between antibodies and manufacturers .

How should researchers select an appropriate TMSB10 antibody for their specific experiments?

Selection should be methodical and based on:

• Target epitope: Determine whether N-terminal (aa 1-12/1-14), C-terminal, or full-length (aa 1-44) antibodies are most appropriate for your research question

• Host species: Consider rabbit polyclonal for wider epitope recognition or mouse monoclonal for higher specificity and reproducibility

• Validated applications: Confirm the antibody has been specifically validated for your application of interest (e.g., WB, IHC, ELISA)

• Species reactivity: Verify cross-reactivity if working with non-human models - many TMSB10 antibodies react with human, mouse, and rat samples due to high sequence conservation

• Published validation: Review literature using your antibody of interest or request validation data from manufacturers

For cancer studies specifically, antibodies validated in the relevant tumor type provide greater confidence in experimental outcomes .

What are optimal protocols for TMSB10 detection in immunohistochemistry across different cancer tissues?

Successful TMSB10 IHC staining requires attention to several methodological details:

Standardized Protocol Based on Literature:

• Tissue preparation: Fix tissues in 4% formalin for 12 hours at room temperature

• Dehydration and embedding: Standard paraffin embedding protocols

• Sectioning: Generate 4μm sections for optimal staining

• Antigen retrieval: Blocking with xylene and paraffin (1:1) for 2 hours at room temperature

• Primary antibody: Incubate with rabbit TMSB10 polyclonal antibody (1:100 dilution) at 4°C overnight

• Secondary antibody: Incubate with goat anti-rabbit secondary antibodies at room temperature for 2 hours

• Visualization: Standard DAB detection systems followed by light microscopy

Scoring System for Quantification:

• Score proportion of TMSB10-expressing cells as: 1 (<25%), 2 (25-50%), 3 (50-75%), or 4 (>75%)

• Score staining intensity: 0 (no staining), 1 (weak, light yellow), 2 (moderate, yellowish-brown), 3 (strong, brown)

• Calculate final score by multiplying these values (range 0-12)

• Define high expression with scores >6 and low expression with scores ≤6

Computer-assisted image analysis (e.g., AxioVision Rel.4.6) can be employed for standardized quantification .

How should researchers troubleshoot inconsistent results when using TMSB10 antibodies?

When facing inconsistent results, implement this systematic troubleshooting approach:

• Antibody validation checks:

  • Perform positive control tests with cell lines known to express TMSB10 (e.g., HEK293, NTera-2)

  • Include negative controls by omitting primary antibody or using tissues with known negative expression

• Technical optimization:

  • For Western blots: Test multiple protein extraction methods as TMSB10 is a small protein (5 kDa) that can be lost in standard protocols

  • For IHC: Optimize antigen retrieval methods, as TMSB10 epitopes may be masked differently in various tissues

• Result interpretation checks:

  • Be aware that methylation status can affect TMSB10 expression independently of antibody performance

  • Acknowledge discordant values between methylation status and protein expression observed in some tissues

• Biological complexity considerations:

  • Control for tissue heterogeneity by ensuring representative sampling

  • Note that TMSB10 expression varies drastically by cancer type (oncogenic in most cancers but reportedly tumor-suppressive in ovarian cancer and cholangiocarcinoma)

What methodologies exist for quantifying TMSB10 in patient serum for diagnostic applications?

Developing serum TMSB10 detection methods requires careful consideration:

ELISA Methodology for Serum TMSB10 Detection:

• Plate preparation: Coat polystyrene microtiter plate with anti-TMSB10 antibody (e.g., sc-514,309) overnight at 4°C

• Washing: Remove unbound antibody with PBST buffer

• Standard curve: Prepare TMSB10 standard curve ranging from 10-300 ng/mL

• Sample incubation: Add patient serum samples (alongside standards) and incubate for 2 hours at 37°C

• Detection: Incubate with goat anti-mouse IgG-HRP for 1 hour followed by TMB substrate addition for 30 minutes

• Signal development: Stop reaction with 2M H₂SO₄ and measure absorbance at 450 nm

Critical Considerations:

• ROC curve analysis should be performed to determine optimal cutoff values for diagnosing specific cancer types

• Pre-analytical variables including sample collection, handling, and storage must be standardized

• Validation through comparison with established tumor markers is essential for clinical application

Research has shown significantly elevated serum TMSB10 levels in colorectal cancer patients compared to healthy controls, suggesting potential diagnostic utility .

How can TMSB10 antibodies be utilized to investigate tumor microenvironment and immune infiltration?

TMSB10's relationship with tumor microenvironment can be explored through:

Multiplex Immunohistochemistry Approach:

• Design a panel including TMSB10 antibody alongside markers for:

  • Cancer-associated fibroblasts (CAFs)

  • Immune cell populations (B cells, T cells, neutrophils, macrophages)

  • Endothelial cells and eosinophils

• Perform sequential staining protocols with appropriate antibody stripping between rounds

• Apply multispectral imaging techniques for simultaneous visualization of markers

• Quantify spatial relationships between TMSB10-expressing cells and immune infiltrates

Correlation Analysis with Immune Scores:

• Assess TMSB10 expression in tumor samples using validated antibodies

• Calculate immune infiltration scores using established algorithms:

  • ImmuneScore, StromalScore and ESTIMATE Score

  • MCP-counter method, EPIC tool, and xCell algorithm

• Perform correlation analyses between TMSB10 expression and immune parameters

• Categorize patients by TMSB10 expression level and compare immune infiltration patterns

Research has demonstrated significant positive correlations between TMSB10 expression and immune cell infiltration in various cancers, particularly kidney cancer (KICH, KIRC), glioma (LGG), and liver cancer (LIHC) .

What experimental designs can investigate TMSB10's role in immunotherapy response prediction?

To explore TMSB10 as an immunotherapy response biomarker:

In Vitro Experimental Design:

• Establish cell line models with differential TMSB10 expression:

  • Generate TMSB10 knockdown lines using siRNA techniques (e.g., si-TMSB10 sequence: 5′-GAG AAG CGG AGT GAA ATT T-3′)

  • Create TMSB10 overexpression models using appropriate vectors

• Assess expression of immune checkpoint molecules (PD-L1, CTLA-4) in these models

• Measure response to immune checkpoint inhibitors in co-culture systems with immune cells

• Explore signaling pathway connections through Western blot detection of key intermediates:

  • STAT3 phosphorylation levels

  • PI3K/AKT pathway activation

Clinical Correlation Methodology:

Research has shown TMSB10 expression correlates with immunotherapy response in datasets like the Checkmate cohort, with high TMSB10 expression predicting poorer response to anti-PD-L1 therapy .

How can researchers investigate the relationship between TMSB10 expression, methylation patterns, and antibody detection sensitivity?

To study TMSB10 epigenetic regulation and its impact on antibody detection:

Integrated Methylation-Expression Analysis Protocol:

• Collect paired tumor and normal tissue samples

• Bisulfite sequencing of the TMSB10 promoter region to establish methylation patterns

• Methylation-specific PCR (MSP) to identify methylated and unmethylated alleles

• Parallel protein detection using validated TMSB10 antibodies via IHC and Western blot

• Treatment of cell lines with demethylating agents (e.g., 5-AzadC) to assess expression changes

• Correlation analysis between methylation status and protein expression

Key Technical Considerations:

• Account for allele-specific methylation effects on expression

• Assess cell line models with known methylation status (e.g., H226 cells with one methylated and one unmethylated allele)

• Control for antibody epitope availability potentially affected by protein modifications

Research has revealed discordant values between TMSB10 methylation status and protein expression in some tissues, suggesting that "promoter hypomethylation may not be a common mechanism underlying TMSB10 overexpression" .

What methodological approaches can determine if TMSB10 is a suitable therapeutic target in specific cancer types?

To evaluate TMSB10 as a potential therapeutic target:

Comprehensive Target Validation Workflow:

• Expression analysis:

  • Quantify TMSB10 levels across cancer subtypes using validated antibodies

  • Compare with matched normal tissues to establish cancer specificity

  • Correlate with established prognostic markers to confirm clinical relevance

• Functional assessment:

  • Perform knockdown studies using siRNA (sequence: 5′-GAG AAG CGG AGT GAA ATT T-3′)

  • Assess phenotypic changes in proliferation, migration, and invasion

  • Examine effects on key signaling pathways:

    • PI3K/AKT pathway

    • VEGF expression

    • p38 phosphorylation in colorectal cancer models

• Therapeutic vulnerability testing:

  • Combine TMSB10 inhibition with standard chemotherapeutics to assess synergistic effects

  • Evaluate TMSB10's relationship with chemotherapy resistance/sensitivity using correlation analyses

  • Examine impact on cancer stem cell properties and therapy resistance mechanisms

Research has demonstrated that TMSB10 knockdown impairs proliferation of ccRCC cells and attenuates invasion in vitro, suggesting therapeutic potential . Furthermore, TMSB10 has shown value in predicting chemotherapy sensitivity in certain cancer types .